Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Renalytix Ai PLC

Market Cap 10.98M 9.58M 8.86M 8.3M 15.54M 1.04B 15.67M 105M 40.75M 510M 41.23M 40.34M 1.77B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 15.58M 13.59M 12.57M 11.78M 22.05M 1.47B 22.23M 149M 57.81M 724M 58.49M 57.24M 2.51B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
73.31%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 2018-03-14
Director of Finance/CFO 68 2024-05-27
President 65 2024-04-29
Director TitleAgeSince
Chairman 74 -
Director/Board Member 52 2024-12-01
Chairman 62 2024-11-04
Change 5-day change 1-year change 3-year change Capi.($)
+11.48%+33.33% - - 10.98M
-1.89%-7.87%-1.02%-29.61% 15.63B
-2.00%-5.63%+28.64%+51.43% 1.57B
+0.19%+1.50%-26.49%+23.17% 1.12B
+4.11%-3.26%-51.75%-84.40% 932M
+5.56%+4.30%-14.86%-51.11% 677M
+0.58%-2.73%-40.15%-58.91% 554M
+3.24%-4.62%+37.29%-54.10% 444M
-1.26%-0.32%-54.06%-62.18% 382M
-3.12%-1.01%-24.84%-23.58% 341M
Average +1.69%-1.75%-16.36%-32.14% 2.41B
Weighted average by Cap. -1.13%-6.14%-4.33%-25.77%

Financials

2024 2025
Net sales 2.29 2 1.85 1.73 3.24 215.88 3.26 21.92 8.49 106.28 8.59 8.41 369.16 3 2.62 2.42 2.27 4.25 282.93 4.28 28.72 11.13 139.29 11.26 11.02 483.83
Net income -33.46M -29.17M -26.98M -25.28M -47.35M -3.16B -47.72M -320M -124M -1.55B -126M -123M -5.4B -20.4M -17.79M -16.45M -15.42M -28.87M -1.92B -29.1M -195M -75.68M -947M -76.57M -74.92M -3.29B
Net Debt 3.86M 3.36M 3.11M 2.91M 5.46M 364M 5.5M 36.91M 14.3M 179M 14.47M 14.16M 622M 4.6M 4.01M 3.71M 3.48M 6.51M 434M 6.56M 44.04M 17.07M 214M 17.26M 16.89M 742M
Logo Renalytix Ai PLC
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!